Your browser doesn't support javascript.
loading
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy.
Horisberger, Alice; La Rosa, Stefano; Zurcher, Jean-Philippe; Zimmermann, Stefan; Spertini, Francois; Coukos, George; Obeid, Michel.
Afiliación
  • Horisberger A; Department of Medicine, Division of Immunology and Allergy, Lausanne University Hospital CHUV, rue du Bugnon 46, CH-1011, Lausanne, Switzerland.
  • La Rosa S; Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital CHUV, rue du Bugnon 25, CH-1011, Lausanne, Switzerland.
  • Zurcher JP; Department of Oncology, Lausanne University Hospital CHUV, rue du Bugnon 46, CH-1011, Lausanne, Switzerland.
  • Zimmermann S; Department of Oncology, Lausanne University Hospital CHUV, rue du Bugnon 46, CH-1011, Lausanne, Switzerland.
  • Spertini F; Department of Medicine, Division of Immunology and Allergy, Lausanne University Hospital CHUV, rue du Bugnon 46, CH-1011, Lausanne, Switzerland.
  • Coukos G; Department of Oncology, Lausanne University Hospital CHUV, rue du Bugnon 46, CH-1011, Lausanne, Switzerland.
  • Obeid M; Ludwig Institute for Cancer Research, University of Lausanne, chemin des Boveresses 155, CH-1066, Epalinges, Switzerland.
J Immunother Cancer ; 6(1): 156, 2018 12 27.
Article en En | MEDLINE | ID: mdl-30587227
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Estenosis Esofágica / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos / Nivolumab Tipo de estudio: Risk_factors_studies Límite: Aged / Humans / Male Idioma: En Revista: J Immunother Cancer Año: 2018 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Estenosis Esofágica / Anticuerpos Monoclonales Humanizados / Antineoplásicos Inmunológicos / Nivolumab Tipo de estudio: Risk_factors_studies Límite: Aged / Humans / Male Idioma: En Revista: J Immunother Cancer Año: 2018 Tipo del documento: Article País de afiliación: Suiza